Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Novavax Quadrivalent vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | - |
| Group 2 | EXPERIMENTAL | - |
| Group 3 | EXPERIMENTAL | - |
| Group 4 | EXPERIMENTAL | - |
| Group 5 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Novavax Quadrivalent vaccine | BIOLOGICAL | Quadrivalent VLP vaccine: low dose; intramuscular injection, deltoid |
| Novavax Trivalent vaccine | BIOLOGICAL | Trivalent Dose; intramuscular injection, deltoid |
| cTIV | BIOLOGICAL | Preconfigured dose; intramuscular injection, deltoid |
Inclusion Criteria: 1. Healthy adult male or females, 18-64 years of age 2. Willing and able to give informed consent prior to study enrollment 3. Able to comply with study requirements 4. Women who are not post-menopausal (≥ 50 years of age and at least one year post last menses) or surgically ste...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
The Novavax Quadrivalent vaccine is an investigational vaccine developed by Novavax, Inc. for the prevention of seasonal influenza. It is a virus-like particle vaccine designed to target four influenza virus strains, and it has been studied in a Phase 2 clinical trial in healthy young adults.
The Novavax Quadrivalent vaccine is being developed for the prevention of influenza, a seasonal infectious disease. It is intended to protect against four influenza virus strains in a single formulation. The vaccine has been evaluated in a Phase 2 study in healthy adults aged 18 years and older.
The Novavax Quadrivalent vaccine is developed by Novavax, Inc., a biopharmaceutical company that trades on the Nasdaq under the ticker symbol NVAX. Novavax focuses on vaccine development, and this quadrivalent influenza candidate is part of its infectious disease pipeline.
The Novavax Quadrivalent vaccine is in Phase 2 development. Its only recorded clinical trial, NCT01561768, was a completed Phase 2 study. The vaccine is investigational and has not been approved by the FDA for any indication.
The Novavax Quadrivalent vaccine has been studied in one clinical trial, NCT01561768, titled "A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young Adults." This completed Phase 2 trial enrolled 500 participants in Australia and was randomized, double-blind, and controlled.
The Phase 2 trial of the Novavax Quadrivalent vaccine, NCT01561768, was a randomized, double-blind, controlled study that enrolled 500 healthy volunteers aged 18 years and older in Australia. It evaluated the immune response and safety of the seasonal virus-like particle influenza vaccine in healthy young adults.